Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for MDXG.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 -10.03M
March 31, 2026 1.879M
December 31, 2025 24.96M
September 30, 2025 29.33M
June 30, 2025 14.42M
March 31, 2025 5.299M
December 31, 2024 19.88M
September 30, 2024 19.62M
June 30, 2024 21.81M
March 31, 2024 4.877M
December 31, 2023 10.26M
September 30, 2023 12.79M
June 30, 2023 7.775M
March 31, 2023 -4.048M
December 31, 2022 -5.624M
September 30, 2022 0.959M
June 30, 2022 -3.005M
March 31, 2022 -10.22M
December 31, 2021 -3.232M
September 30, 2021 6.33M
June 30, 2021 1.599M
March 31, 2021 -6.679M
December 31, 2020 -10.27M
September 30, 2020 -4.618M
June 30, 2020 -3.097M
Date Value
March 31, 2020 -12.28M
December 31, 2019 -23.12M
September 30, 2019 -3.16M
June 30, 2019 2.13M
March 31, 2019 -15.26M
December 31, 2018 1.534M
September 30, 2018 3.397M
June 30, 2018 20.69M
March 31, 2018 10.18M
December 31, 2017 20.86M
September 30, 2017 17.95M
June 30, 2017 13.48M
March 31, 2017 10.64M
December 31, 2016 16.76M
September 30, 2016 2.80M
June 30, 2016 7.219M
March 31, 2016 -0.977M
December 31, 2015 4.356M
September 30, 2015 7.308M
June 30, 2015 2.933M
March 31, 2015 4.21M
December 31, 2014 8.284M
September 30, 2014 8.949M
June 30, 2014 1.179M
March 31, 2014 -1.611M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Anika Therapeutics, Inc. -0.684M
Perspective Therapeutics, Inc. -20.65M
ABVC BioPharma, Inc. -0.2444M
Enovis Corp. 75.03M
Edwards Lifesciences Corp. 651.90M